全国唑来膦酸致颌骨骨坏死不良反应监测数据分析

doi:10.19803/j.1672-8629.2022.06.12

中国药物警戒 ›› 2022, Vol. 19 ›› Issue (6): 641-644.
DOI: 10.19803/j.1672-8629.2022.06.12

全国唑来膦酸致颌骨骨坏死不良反应监测数据分析

熊玮仪, 任经天^*

国家药品监督管理局药品评价中心,国家药品监督管理局药物警戒研究与评价重点实验室,北京 100022

收稿日期:2021-11-29 出版日期:2022-06-15 发布日期:2022-06-13
通讯作者: ^* 任经天,男,博士,主任药师,药品不良反应监测。E-mail：renjingtian@cdr-adr.org.cn
作者简介:熊玮仪,女,博士,副研究员,流行病学与药品不良反应监测。

Analysis of national monitoring data of adverse drug reactions related to zoledronic acid-related osteonecrosis of the jaw

XIONG Weiyi, REN Jingtian^*

Center for Drug Reevaluation, NMPA/ NMPA Key laboratory for Research and Evaluation of Pharmacovigilance, Beijing 100022, China

Received:2021-11-29 Online:2022-06-15 Published:2022-06-13

摘要/Abstract

摘要： 目的描述我国唑来膦酸致颌骨骨坏死（ONJ）不良反应的报告特征,探索影响因素,为风险控制提供建议。方法对2004年1月1日至2021年6月30日期间国家药品不良反应监测系统收到的唑来膦酸致ONJ不良反应报告进行统计分析。结果共73份唑来膦酸致ONJ报告,90.41%为严重报告。2份信息缺失,其余71份中,94.37%（67/71）为肿瘤用药,5.63%（4/71）为骨质疏松症用药。肿瘤报告以中老年女性为主,44.78%的原发肿瘤为乳腺癌,59.70%有合并治疗,41.79%有牙科手术史,52.24%的ONJ转归为痊愈或好转。4份骨质疏松症报告均为有牙科手术史的老年女性。结论我国唑来膦酸致ONJ报告较为罕见,但多为严重报告。肿瘤患者多于骨质疏松症患者,牙科手术史是需要重视的危险因素,合并治疗对ONJ的发生可能有一定影响。药品上市许可持有人、医务人员、患者均应重视唑来膦酸的ONJ风险,采取多种措施保障用药安全。

关键词: 唑来膦酸, 颌骨骨坏死, 药品不良反应

Abstract: Objective To describe the characteristics of zoledronic acid related osteonecrosis of the jaw (ONJ) in China, explore the risk factors, and to give tips about risk control. Methods Zoledronic acid related ONJ reports received by the National Adverse Drug Reaction Monitoring System between January 1, 2004 and June 30, 2021 were analyzed to identify the characteristics of ONJ reports. Results A total of 73 zoledronic acid related ONJ reports were retrieved, 90.41% of which were serious reports. The information about 2 cases was missing. Among the 71 cases reported, 94.37% (67/71) were related to anti-tumor drugs and 5.63% (4/71) anti-osteoporosis drugs. Cancer-related reports mainly involved middle-aged and elderly women. 44.78% of primary tumors were breast cancer, 59.70% of the patients had received concomitant therapies, 41.79% had undergone dental surgery, and 52.24% had fully recovered or were recovering. The four reports about osteoporosis patients were all elderly women with a dental surgery history. Conclusion Zoledronic acid related ONJ is rarely reported in China, most of the reports involve serious cases. There have been more reports from patients with cancer than from patients with osteoporosis. A dental surgery history is an important risk factor for ONJ, and the concomitant therapy might have some effect on the onset of ONJ. The risk of ONJ induced by zoledronic acid deserves more attention and effective measures should be taken to ensure drug safety.

Key words: zoledronic acid, osteonecrosis of the jaw, adverse drug reaction

中图分类号:

R994.1

熊玮仪, 任经天. 全国唑来膦酸致颌骨骨坏死不良反应监测数据分析[J]. 中国药物警戒, 2022, 19(6): 641-644.

XIONG Weiyi, REN Jingtian. Analysis of national monitoring data of adverse drug reactions related to zoledronic acid-related osteonecrosis of the jaw[J]. Chinese Journal of Pharmacovigilance, 2022, 19(6): 641-644.

参考文献

[1] Breast Cancer Group, Chinese Medical Doctor Association, International Medical Scociety, Chinese Anti-cancer Association. Expert consensus on safety management of bone-modifying agents[J]. Chinese Journal of Oncology(中华肿瘤杂志), 2021, 43(6): 622-628.
[2] MARX RE.Pamidronate (aredia) and zoledronate (zometa) induced avascular necrosis of the jaws: a growing epidemic[J]. Journal of Oral and Maxillofacial Surgery, 2003, 61(9): 1115-1118.
[3] BLACK DM, DELMAS PD, EASTELL R, et al.Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis[J]. The New England Journal of Medicine, 2007, 356(18): 1809-1822.
[4] CARTSOS VM, ZHU SH, ZAVRAS AI.Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people[J]. The Journal of the American Dental Association, 2008, 139(1): 23-30.
[5] KHAN AA, SANDOR GK, DORE E, et al.Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw[J]. The Journal of Rheumatology, 2008, 35(7): 1391-1397.
[6] European Medicines Agency. Further measures to minimize risk of osteonecrosis of the jaw with bisphosphonate medicine[EB/OL].(2015-03-27) [2021-11-22]. https://www.ema.europa.eu/en/news/further-measures-minimise-risk-osteonecrosis-jaw-bisphosphonate-medicine.
[7] North Central London Joint Formulary Committee. Summary of MHRA alerts for bisphosphonates and denosumab[EB/OL].(2021-08-04)[2021-11-22].https://www.ncl-mon.nhs.uk/wp-content/uploads/Guidelines/10_Bisphosphonate_Denosumab_MHRA_Summary.pdf.
[8] State Food and Drug Administration. Adverse drug reaction information bulletin (Issue 37) Serious adverse reactions of bisphosphonate drugs[EB/OL].(2011-04-15)[2021-11-22]. https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/yjjsh/ypblfytb/20110415120001267.html.
[9] Ministry of Health of the People's Republic of China. Provisions for adverse drug reaction reporting and monitoring (Decree of the MOH, No.81)[EB/OL].(2011-05-45)[2021-11-22]. https://www.nmpa.gov.cn/yaopin/ypfgwj/ypfgbmgzh/20110504162501325.html.
[10] WANG FF, CHEN WH, HE ZQ, et al.Analysis of literature and clinical cases of adverse drug reactions induced by zoledronic acid injection[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(4): 223-227.
[11] European Medicines Agency. Questions and answers on the review of bisphosphonates and the risk of osteonecrosis of the jaw[EB/OL].(2009-09-24)[2021-11-22]. https://www.ema.europa.eu/en/documents/other/questions-answers-review-bisphosphonates-risk-osteonecrosis-jaw_en.pdf.
[12] National Medical Products Administration. Announcement of national medical products administration on revising the instructions for zoledronic acid injection (No. 128 of2021)[EB/OL].(2021-10-28)[2021-11-22]. https://www.nmpa.gov.cn/xxgk/ggtg/ypshmshxdgg/20211028170039141.html.
[13] National Center for ADR Monitoring. Reporting requirement// Provisions for adverse drug reaction reporting and monitoring training materials(相关表格填写要求//《药品不良反应报告和监测管理办法》培训教材)[M]. Beijing: China Medical Science Press, 2012.
[14] National Center for ADR monitoring. Notice on the issuance of the “Adverse Drug Reaction Report Form for Marketing Authorization Holders”and the instructions for reporting[EB/OL].(2020-01-08)[2021-11-22]. https://www.cdr-adr.org.cn/drug_1/zcfg_1/zcfg_zdyz/202001/t20200108_47026.html.

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[4]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[5]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[6]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[7]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[8]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[9]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[10]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[11]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[12]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[13]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[14]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[15]	刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006.

全国唑来膦酸致颌骨骨坏死不良反应监测数据分析

Analysis of national monitoring data of adverse drug reactions related to zoledronic acid-related osteonecrosis of the jaw

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics